Lonza received Swissmedic approval for a new aseptic filling line in Stein capable of handling highly potent biologics and ADCs, expanding its drug product footprint and containment capabilities. The line meets GMP Annex 1 sterile manufacturing requirements and integrates advanced isolator technology to support clinical and commercial supply chains. Separately, MilliporeSigma (Merck KGaA’s life science arm) agreed to acquire JSR Life Sciences’ chromatography business to bolster downstream processing capabilities, notably Protein A resins used in mAb purification. The transaction aims to expand global support for monoclonal antibody manufacturing and accelerate process scale‑up for customers. These moves reflect continued industry investment in CDMO capacity for complex biologics, including ADCs and gene‑delivery modalities, as biopharma firms prioritize supply security and faster pathways from clinic to market.